- About Us
- Nano-Social Network
- Nano Consulting
- My Account
September 7th, 2004
Ventana and Quantum Dot Announce Agreement
Ventana Medical Systems, Inc. and Quantum Dot Corporation announced comprehensive licensing and supply agreements relating to QDC's QdotŪ nanocrystal technology for in vitro diagnostic applications in Anatomic Pathology and Cytology.
Ventana and Quantum Dot Announce Agreement
Tucson, AZ, and Hayward, CA . September 7th, 2004
Ventana Medical Systems, Inc. (Nasdaq: VMSI), and Quantum Dot Corporation (QDC) announced comprehensive licensing and supply agreements relating to QDC's QdotŪ nanocrystal technology for in vitro diagnostic applications in Anatomic Pathology and Cytology. Ventana will also incorporate QDC technology in its research and pharmaceutical discovery platforms. Under the terms of the agreement, QDC will supply Qdot nanocrystals for Ventana's incorporation into next-generation rapid, quantitative, and multiplexed assays for cancer diagnosis and disease management. Financial terms of the agreement were not disclosed.
"As a leading provider of automated diagnostic solutions, Ventana is committed to identifying those technologies that enable us to effectively address the increasing demands placed on the anatomical pathology laboratory in the important role they play in improving patient care," stated Christopher Gleeson, President and Chief Executive Officer of Ventana. "Quantum Dot's expertise and intellectual property provide tools for Ventana to extend our leadership position in tissue-based molecular diagnostics, and we look forward to a very productive partnership."
"The choice of our Qdot nanocrystals for Ventana's expansion into fluorescent in vitro diagnostics continues to validate the value of our technology," commented George Dunbar, QDC's Chief Executive Officer. "Leveraging Ventana's development expertise and worldwide sales and distribution capabilities is an effective way to provide Qdot nanocrystal products to anatomic pathology customers. This is a good model for future field-defined partnerships for our company."
About Ventana Medical Systems, Inc.
Ventana develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in clinical histology and drug discovery laboratories worldwide. Ventana's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.
About Quantum Dot Corporation (www.qdots.com)
Quantum Dot is a privately held bioscience company that has pioneered the development and commercialization of QdotŪ nanocrystals for bio-detection in discovery and clinical applications. QDC's current products include more than 40 life science kits and applications, used by life science discovery laboratories worldwide. QDC will soon be launching its first integrated instrumentation, software, and bio-reagents platform, the Mosaic system, for rapid and quantitative multiplexed gene expression analysis. QDC collaborates with leading academic and industrial partners and has over 130 patents and patents-pending.
Any statements made about the Ventana's anticipated success of product development activities and product development are forward-looking statements subject to risks and uncertainties, such as the risks inherent in the development, manufacturing, marketing and sale of medical products, competitive factors, general economic conditions, legal disputes, and government actions as more fully described in Ventana's Annual Report on Form 10-K for the year ended December 31, 2003. Actual results may differ materially from anticipated results.
Ventana Medical Systems Contacts:
Christopher M. Gleeson
President and CEO
Chief Financial Officer
Quantum Dot Corporation Contacts:
Copyright Ventana Medical Systems and Quantum Dot Corporation. Reprinted with permission.
If you have a comment, please us.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
In-cell molecular sieve from protein crystal February 14th, 2017
Particle Works creates range of high performance quantum dots February 23rd, 2017
GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017